Rubius Therapeutics, a “Fierce 15” company pioneering the creation of a
new class of extraordinarily active, ready-to-use and life-changing
cellular therapies, today announced the appointment of Chris Carpenter,
M.D., Ph.D., as chief medical officer. Dr. Carpenter will oversee
Rubius’ clinical and regulatory strategy as the Company prepares to
enter human clinical trials in 2018. In addition, Rubius announced the
appointments of Joanne Protano as vice president of finance; Mark Boshar
as vice president of legal affairs; and Theo Proukou as vice president
of human resources.

“We are delighted to welcome Chris, Joanne, Mark and Theo to the team,
and look forward to their leadership and leveraging their decades of
pharmaceutical and biotech experience as we work to lead the next
generation of cellular therapies,” said Torben Straight Nissen, Ph.D.,
president of Rubius Therapeutics. “Chris and the rest of the team will
play a pivotal role in bringing the promise of red cell therapeutics to
the clinic in 2018.”

“Rubius is transforming the way we think about cellular therapies and
developing an entirely new class of ready-to-use cell therapeutics to
treat cancer, enzyme deficiency disorders and autoimmune diseases
through the induction of tolerance,” said Chris Carpenter, M.D., Ph.D.
“The next year is primed to be an exciting one for the Company, and I am
thrilled to join a group of people so passionate and committed to
bringing life-changing products to patients as soon as possible.”

Dr. Carpenter most recently served as senior vice president and head of
the cancer epigenetics department at GlaxoSmithKline, where he was
responsible for the overall strategy, as well as the identification and
validation of new epigenetic targets and advancing novel therapies
through clinical proof of concept. While at GSK, Dr. Carpenter also led
the development of Votrient (pazopanib). Prior to GSK, he was at Merck
and led the development of MK-4827, which became Tesaro’s Zejula. Prior
to Merck, Dr. Carpenter led a laboratory at Harvard Medical School for
14 years after having completed a clinical fellowship in
hematology/oncology at Massachusetts General Hospital and a
post-doctoral fellowship in Lewis Cantley’s laboratory. Dr. Carpenter
received his M.D. and Ph.D. from the University of Southern California
and B.S. from Stanford University.

Joanne Protano joined Rubius from Flagship Pioneering, most recently
serving as senior vice president of finance, new ventures, where she was
responsible for the financial and administrative operations of
early-stage portfolio companies. Before that, Joanne held senior
financial roles in public technology and biotechnology companies,
including as vice president and chief financial officer of Cellectar
Biosciences. She started her career at Deloitte LLP.

Mark Boshar brings more than 25 years in the biotechnology industry
focused on intellectual property and transactional law, including
licensing and pharma partnering. Most recently, he served as a legal
advisor and business consultant to a number of early-stage companies.
Previously, he founded the legal department at Millennium
Pharmaceuticals (now Takeda Oncology) and served as its associate
general counsel and chief patent counsel for several years. Mark began
his legal career as an attorney with the law firm of Hale and Dorr (now
WilmerHale). Prior to that, Mark was a scientist at Genetics Institute
and the Worcester Foundation.

Theo Proukou brings nearly 20 years of human resources experience in the
pharmaceutical and biotechnology industry. He spent 16 years at Novartis
Pharmaceuticals holding numerous roles with increasing responsibilities
in human resources, marketing and sales. In 2014, Theo joined Vertex
Pharmaceuticals leading the HR team for commercial and G&A. In 2015, he
was promoted to vice president of talent acquisition and development
where he led efforts to recruit, retain and develop talent across the
organization. In 2016, Theo joined TripAdvisor, where he led the global
HR business partner organization until coming to Rubius earlier this
summer.

“Rubius’ ability to attract this caliber of talent for its management
team validates the promise and potential that this technology holds for
developing important new treatments for patients,” said David Epstein,
executive chairman of Rubius. “With this team and our recent $120
million financing, we are well prepared to deliver against several key
goals for our Red Cell Therapeutics™ platform in 2018.”

About Rubius Therapeutics

Rubius Therapeutics, a 2017 “Fierce 15” award winner, is creating
Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a
wide array of indications. Leading applications include programs in
cancer, rare and autoimmune disease, as well as additional potential in
infectious and metabolic diseases. The company was conceived and
launched by Flagship VentureLabs®, the institutional
innovation foundry where a team of scientific entrepreneurs
systematically evolves enterprising ideas into new fields, or previously
undiscovered areas of science into real-world inventions and ventures.
The company was founded by Flagship Pioneering in 2014 and has been
capitalized with $140 million to date. For more information please visit
us at www.rubiustx.com.

About Red-Cell Therapeutics™

Red-Cell Therapeutics™ are genetically engineered, enucleated red cells
that are being developed to provide allogeneic, off-the-shelf therapies
to patients across multiple therapeutic areas. RCT advantages over other
therapies include immuno-privileged presentation of proteins within or
on the red cell, high target avidity and affinity resulting in highly
potent and selective therapies, and long circulation half-life. Rubius
RCTs exhibit fundamentally unique biology and have been engineered to
replace missing enzymes for patients living with a variety of rare
diseases, to kill tumors, and upregulate or downregulate the immune
system to treat both cancer and autoimmune disorders.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.